Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings 27 November 2023
First African-manufactured combination therapy for seasonal malaria chemoprevention receives WHO prequalification 6 November 2023 Universal Corporation Ltd (UCL), a Strides Pharma Science Limited (Strides) enterprise, with support from MMV, has become the first African manufacturer to gain WHO prequalification for their sulfadoxine-pyrimethamine + amodiaquine product.
Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria 21 August 2023
Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria 6 June 2023
Medicines for Malaria Venture and the Africa CDC sign Memorandum of Understanding to support African manufacturers 15 December 2022
Strong recommendation for pyronaridine-artesunate in revised WHO Malaria Treatment Guidelines 25 November 2022
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria 23 November 2022
First African-manufactured medicine to prevent malaria in pregnant women and infants quality-approved by WHO 25 August 2022
MMV and IVCC make 240 compounds available to stimulate research into new drugs and insecticides 13 August 2022
Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration 14 March 2022
Novartis and Medicines for Malaria Venture report positive results for Phase IIb study of novel ganaplacide/lumefantrine combination in children with malaria 29 September 2021
New partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide 14 July 2021
Pyronaridine-artesunate demonstrates high real-life safety, tolerability and effectiveness in the treatment of uncomplicated malaria in large multi-country study in Africa 17 June 2021
This World Malaria Day MMV recognizes Swiss Malaria Group's commitment to defeating malaria 19 April 2021
New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010 28 January 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration 8 January 2021
Global call to boost access to lifesaving malaria treatment for pregnant women in Africa 15 October 2020
Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria 24 April 2020
